Cardiovascular and Endothelial Benefits GLP-1 RAs have demonstrated robust cardiovascular protection in multiple large-scale trials, including LEADER, REWIND, and SUSTAIN-6, showing reduced rates of major adverse cardiac events independent of weight loss
The orforglipron analysis looks at an oral GLP-1 agonist in development
In TRIUMPH-4, the 12mg group had higher rates of dysesthesia (20.9% vs
The lowest Phase 2 obesity arm was 1 mg weekly and produced 8.7% weight loss at 48 weeks, but the calculator starts below the trial dose to create a slower adaptation ladder
Studies show that GLP-1S stimulates glucose-dependent insulin secretion, suppresses glucagon release from pancreatic alpha cells, slows gastric emptying, and influences satiety signaling via the central nervous system
2025 Feb 1;14(3):944